Nairobi, Kenya | 11 May 2026 – Africa CDC congratulates Biovac and Proparco on the announcement of this important investment collaboration on the sidelines of the Africa Forward Summit.
This milestone represents another significant step forward in advancing Africa’s Health Security and Sovereignty Agenda through strategic investments in local vaccine manufacturing capacity.
The mobilisation of US$180 million to support the expansion of a multi-vaccine manufacturing facility, including technology transfer, production scale-up, and working capital, demonstrates growing confidence in Africa’s pharmaceutical manufacturing potential and the strength of partnerships committed to strengthening the continent’s health manufacturing ecosystem.
Beyond Proparco, the consortium is supported by other key partners, including the European Investment Bank through the Human Development Accelerator (HDX), and the International Finance Corporation, with further support from African-based DFIs expected to conclude shortly. The European Investment Bank and Proparco’s investments represent half of the funding and have been made possible through European Commission financial guarantees.
Africa CDC also recognises the catalytic role of Gavi, the Vaccine Alliance, and the African Vaccine Manufacturing Accelerator (AVMA) in helping unlock this opportunity and creating a viable pathway for locally manufactured vaccines to reach the market.
Witnessing the signing, Dr Jean Kaseya, Director General of Africa CDC, stated:
“This is a defining moment as the continent accelerates efforts to build sustainable vaccine manufacturing capacity and move toward a future where Africa produces and procures more of its own health products as a central pillar of its Health Security and Sovereignty Agenda.
This investment, led by a consortium of development finance institutions, reflects strong confidence in Africa’s manufacturing potential and reinforces a simple truth: in a world of evolving and unpredictable health threats, local manufacturing capacity is not optional — it is essential.
We also recognise the catalytic role of Gavi and the African Vaccine Manufacturing Accelerator in helping unlock this opportunity and enabling a viable pathway for locally manufactured vaccines to reach the market. Investments such as these are critical to strengthening local manufacturing ecosystems, accelerating technology transfer, and ensuring sustainable and equitable access to African-made vaccines.”
Africa CDC remains committed to working with partners to ensure sustainable demand, accelerate market uptake, and support the long-term success of African vaccine manufacturers. These efforts are essential to advancing the African Union’s ambition of producing 60% of vaccines used on the continent locally by 2040, while strengthening Africa’s preparedness and resilience against future health threats.
###
About Africa CDC
The Africa Centres for Disease Control and Prevention (Africa CDC) is the public health agency of the African Union. As an autonomous institution, Africa CDC supports AU Member States to strengthen health systems, improve disease surveillance, and enhance emergency preparedness and response. For more information, visit: http://www.africacdc.org and follow Africa CDC on LinkedIn, X, Facebook, and YouTube.
Media Contact Africa CDC:
Margaret Muigai Edwin, Director of Communication & Public Information Directorate: Africa CDC | Tel: +255 742 635 592, edwinm@africacdc.org
